Docetaxel Improves Survival in Hormone-Naive Prostate Cancer
Docetaxel should be routine practice in men with newly diagnosed metastatic prostate cancer and selected high-risk non-metastatic disease
Docetaxel should be routine practice in men with newly diagnosed metastatic prostate cancer and selected high-risk non-metastatic disease, according to research presented in an American Society of Clinical Oncology (ASCO) presscast ahead of the 2015 ASCO Annual Meeting.
Specifically, the STAMPEDE trial showed that there was a 38% relative improvement in failure-free survival (hazard ratio: 0.62) in patients with hormone-naive prostate cancer treated with hormone therapy plus docetaxel compared with those treated with hormone therapy alone.
In addition, researchers found that there was a 24% relative improvement in overall survival with hormone therapy and docetaxel versus hormone therapy alone.
RELATED: Lethal Metastatic Prostate Cancer May Spread from Other Sites
The study also showed that zoledronic acid in addition to androgen deprivation therapy (ADT) did not improve survival, but survival was improved when both zoledronic acid and docetaxel were added to ADT. That benefit was similar to the benefit observed from adding docetaxel alone to hormone therapy.
Patients were only included into the study if they were initiating ADT for the first time for high-risk locally advanced disease, lymph node-positive disease, metastatic disease, or had aggressive disease during relapse following surgery or radiotherapy.